Duke Rohlen, CEO
Duke Rohlen has over 15 years of experience as an executive in medical device companies. He currently serves as co-founder and CEO of Spirox, Inc., a medical device company that treats nasal obstruction. Prior to Spirox, Duke helped lead a $7.0 million recapitalization of Advanced Cardiac Therapeutics at a $100,000 pre-money valuation and, as CEO, entered into a structured sale with Abbott Laboratories valued at ~$200.0 million. Prior to Advanced Cardiac Therapeutics, Mr. Rohlen served as founder and CEO of CV Ingenuity. During his tenure at CVI, he raised $30.0 million of venture capital prior to selling the Company to Covidien (now Medtronic) in 2013 for ~$300.0 million. Prior to CV Ingenuity, he served as President of FoxHollow Technologies where he helped drive annual sales to $200.0 million, helped the Company through an IPO, conceived of and structured a $300.0 million collaboration with Merck Pharmaceuticals, and ultimately helped to sell the company to EV3 (now Medtronic) for $780.0 million dollars in 2008.
Prior to working at FoxHollow, Mr. Rohlen held senior management positions at two other medical technology companies and served as an entrepreneur-in-residence at the private equity firm, Alta Partners. Mr. Rohlen began his professional career as the founder and President of a 9 unit, ~$20.0 million per year restaurant company. Mr. Rohlen received an M.B.A. from Harvard Business School and a B.A. from Stanford University.